The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 10, 2012, Pages 1231-1242

  Rohof, W O ^a   Lei, A ^a   Hirsch, D P ^a   Ny, L ^b   Astrand, M ^b   Hansen, M B ^b   Boeckxstaens, G E ^a,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 2066; METABOTROPIC GLUTAMATE RECEPTOR 5 ANTAGONIST; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATTENTION DISTURBANCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; ESOPHAGEAL IMPEDANCE MEASUREMENT; ESOPHAGEAL PH MONITORING; ESOPHAGUS EXAMINATION; ESOPHAGUS MANOMETRY; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN EXPERIMENT; LOWER ESOPHAGUS SPHINCTER; MALE; NORMAL HUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SMOOTH MUSCLE RELAXATION; TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANALYSIS OF VARIANCE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESOPHAGEAL SPHINCTER, LOWER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; POSTPRANDIAL PERIOD; RECEPTORS, METABOTROPIC GLUTAMATE; YOUNG ADULT;

EID: 84859898783     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05081.x     Document Type: Article

References (31)

1. Armstrong D,. Systematic review: persistence and severity in gastroesophageal reflux disease. Aliment Pharmacol Ther 2008; 28: 841-53.
2. Vakil N, Veldhuyzen van Zanten S, Kahrilas P, et al,. The Montreal definition and classification of gastro-esophageal reflux disease (GERD)-a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
3. Dent J, El-Serag HB, Wallander MA, et al,. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 710-17. (Pubitemid 40559260)
4. Wong BCY, Kinoshita Y,. Systematic review on epidemiology of gastroesophageal reflux disease in Asia. Clin Gastroenterol Hepatol 2006; 4: 398-407.
5. Dent J,. Review article: from 1906 to 2006-a century of major evolution of understanding of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006; 24: 1269-81. (Pubitemid 44571558)
6. van Pinxteren B, Numans ME, Bonis PA, et al,. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2001; 4: CD002095.
7. Armstrong D, Pare P, Pericak D, et al,. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001; 96: 2849-57. (Pubitemid 32959523)
8. Fass R,. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs 2007; 67: 1521-30. (Pubitemid 47267295)
9. Hatlebakk JG, Hyggen A, Madsen PH, et al,. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ 1999; 319: 550-3. (Pubitemid 29403637)
10. Meineche-Schmidt V, Hauschildt Juhl H, Ostergaard JE, et al,. Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-oesophageal reflux symptoms in primary care. Aliment Pharmacol Ther 2004; 19: 907-15. (Pubitemid 38534820)
11. El-Serag H, Becher A, Jones R,. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010; 32: 720-37.
12. Dent J, Dodds WJ, Friedman RH, et al,. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 1980; 65: 256-67. (Pubitemid 10159855)
13. Dodds WJ, Dent J, Hogan WJ, et al,. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med 1982; 307: 1547-52. (Pubitemid 13245429)
14. Boeckxstaens GE, Smout A,. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastroesophageal reflux disease. Aliment Pharmacol Ther 2010; 32: 334-43.
15. Penagini R, Carmagnola S, Cantu P, et al,. Mechanoreceptors of the proximal stomach: role in triggering transient lower esophageal sphincter relaxation. Gastroenterology 2004; 126: 49-56. (Pubitemid 38040723)
16. Blackshaw LA,. Receptors and transmission in the brain-gut axis: potential for novel therapies. IV. GABA(B) receptors in the brain- gastroesophageal axis. Am J Physiol Gastrointest Liver Physiol 2001; 281: G311-5.
17. Hirsch DP, Tytgat GN, Boeckxstaens GE,. Transient lower oesophageal sphincter relaxations-a pharmacological target for gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2002; 16: 17-26. (Pubitemid 34123860)
18. Boeckxstaens GE, Beaumont H, Mertens V, et al,. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 2010; 139: 409-17.
19. Boeckxstaens GE, Rydholm H, Lei A, et al,. Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower esophageal sphincter relaxations in male subjects. Aliment Pharmacol Ther 2010; 31: 1208-17.
20. Young RL, Page AJ, O'Donnell TA, et al,. Peripheral versus central modulation of gastric vagal pathways by metabotropic glutamate receptor 5. Am J Physiol Gastrointest Liver Physiol 2007; 292: G501-11.
21. Frisby CL, Mattsson JP, Jensen JM, et al,. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology 2005; 129: 995-1004. (Pubitemid 41242690)
22. Jensen J, Lehmann A, Uvebrant A, et al,. Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist. Eur J Pharmacol 2005; 519: 154-7. (Pubitemid 43181178)
23. Keywood C, Wakefield M, Tack J,. A proof of concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-esophageal reflux disease. Gut 2009; 58: 1192-9.
24. Holloway RH, Penagini R, Ireland AC,. Criteria for objective definition of transient lower esophageal sphincter relaxation. Am J Physiol 1995; 268: G128-33.
25. Senn S,. Cross-over Trials in Clinical Research. 2nd edn. Chichester: Wiley, 2002.
26. Lidums I, Lehmann A, Checklin H, et al,. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 2000; 118: 7-13. (Pubitemid 30020367)
27. Vela MF, Tutuian R, Katz PO, et al,. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003; 17: 243-51. (Pubitemid 36174255)
28. Zhang Q, Lehmann A, Rigda R, et al,. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002; 50: 19-24. (Pubitemid 34028297)
29. Beaumont H, Bennink RJ, de Jong J, et al,. The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. Gut 2010; 59: 441-51.
30. del Genio G, del Genio A, Brusciano L, et al,. Laparoscopic cardioplasty to avoid esophageal resection in patient not responsive to Heller myotomy. Ann Thorac Surg 2007; 83: 2235-8. (Pubitemid 46782614)
31. Del Tacca M, Blandizzi C, Bernardini MC,. Central GABAA excitatory and GABAB inhibitory receptors regulate gastric acid secretion in rats. Eur J Pharmacol 1990; 177: 189-94. (Pubitemid 20088715)